Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Description of Data Sources Utilized to Calculate Drug Treatment Coverage Ratesa

From: Change and variability in drug treatment coverage among people who inject drugs in 90 large metropolitan areas in the USA, 1993–2007

1) Proportion of treatment entrants who indicated that they injected substances intravenously in each MSA and year (1993–2007) as reported by the Treatment Episode Data Set (TEDS) [34];
2) Total number of drug users in drug treatment as of October 1 of each year reported by the Uniform Facility Data Set (UFDS) for 1993, 1995, 1996–1998 [35, 36] and the National Survey of Substance Abuse Treatment Services (N-SSATS) for 2000, 2002–2007 [37];
3) Total estimated number of PWID in each MSA and year (1993–2007) as calculated and reported by Tempalski and colleagues [38]b
  1. aThese data do not capture medication-assisted treatment (MAT) operating out of private medical offices. Additionally, we need to acknowledge much of any system response to the opioid epidemic would have taken place after 2007, and so our data would miss those more recent changes
  2. bOur drug treatment coverage estimates are based on the number of PWID in an MSA. Current data available for PWID are up through 2007